The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Henk M. Lokhorst
Consultant or Advisory Role - Genmab; Janssen
Research Funding - Genmab; Janssen
Jacob Laubach
Research Funding - Novartis; Onyx
Hareth Nahi
No relevant relationships to disclose
Torben Plesner
Consultant or Advisory Role - Genmab; Janssen
Honoraria - Celgene; Genmab; Janssen
Research Funding - Janssen
Expert Testimony - Takeda
Peter Gimsing
No relevant relationships to disclose
Markus Hansson
No relevant relationships to disclose
Monique Minnema
Honoraria - Janssen-Cilag
Ulrik Niels Lassen
No relevant relationships to disclose
Jakub Krejcik
No relevant relationships to disclose
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Steen Lisby
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Linda Basse
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Nikolai C. Brun
Employment or Leadership Position - Genmab
Stock Ownership - Genmab
Paul G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Genmab; Johnson & Johnson; Millennium; Novartis